Meet the CEOs Webcast Replay

This week we were joined by the CEOs of exciting ASX listed businesses, who gave valuable insight to their industries and companies future prospects.

  • (ASX: AVA) Ava Risk Group – Rob Broomfield, Chief Executive Officer
  • (ASX: SEQ) Sequoia Financial Group – Garry Crole, Managing Director
  • (ASX: OCC) Orthocell Limited – Paul Anderson, Managing Director

Recorded on 23rd September 2020 at 12pm (AEST).

Join the next Meet the CEOs webcast

Speak to the Reach Markets team



Chief Executive Officer - Ava Risk Group (ASX: AVA)

Ava Risk Group (ASX: AVA) is a market leader in the provision of risk management services and technologies, trusted by some of the most security conscious commercial, industrial, military and government clients in the world. The Group features a range of complementary solutions including intrusion detection for perimeters, pipelines and data networks, biometric and card access control, as well as the secure international logistics and storage of high value assets. Through decades of innovation, the Ava Group continues to build upon a comprehensive portfolio of premium services and technologies for the most complex and demanding markets.


Managing Director - Sequoia Financial Group (ASX: SEQ)

Sequoia Financial Group Limited (ASX:SEQ) is an integrated financial services company providing products and services to self-directed investors, AFSL holders and third party professional service firms. The expansion of Sequoia Financial Group into corporate advisory, equity capital markets and institutional dealing demonstrates the corporate vision of Sequoia Financial Group as a boutique global investment house known for the quality of its advice, strength of its relationships and depth of expertise across financial markets.


Managing Director - Orthocell Limited (ASX: OCC)

Orthocell Limited (ASX: OCC) is a world-leading regenerative medicine company providing innovative products to restore mobility, function and performance. Its product portfolio includes CelGro®, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications. The Company’s other major focus is TGA-licensed cell therapies Autologous Tenocyte Implantation (Ortho-ATI®) and Autologous Chondrocyte Implantation (Ortho-ACI®), which aim to regenerate damaged tendon and cartilage tissue.

latest other webcasts

Far East Gold (ASX: FEG) Investor Q&A

MDF Global Webcast Replay

Felix Gold (ASX: FXG) Webcast Replay

Speak to the Reach Markets team

What is a 708 investor?

By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement.